Daidzein (one of the major isoflavones) can be metabolized to equol in certain individuals. The effects of isoflavones alone and equol status on lipid profiles are still controversial. To evaluate the 6-mo effects of daidzein on cardiovascular risk factors in hypercholesterolemic individuals and the interactions of these effects with equol status and estrogen receptor (ESR) genotypes, we conducted a randomized, double-blind, placebo-controlled trial consisting of 210 hypercholesterolemic adults 
Introduction
Isoflavones have been shown to promote health in humans and have been linked to an improvement in postmenopausal symptoms and osteoporosis. Daidzein, one of major isoflavones, can be metabolized to equol by gut bacteria in a portion of the population. Equol has higher binding affinity for estrogen receptor (ESR) 7 than daidzein and other isoflavones such as genistein (1). Several clinical studies have concluded that isoflavones may produce better clinical effects in equol producers than in non-equol producers (2,3). Previous studies often used soy or isoflavone extract to assess the interaction of equol status and isoflavone effects (4, 5) . However, the other major isoflavone component, genistein, which cannot produce equol, may confound the contributions of equol status as a result of the effects of isoflavones. Genistein alone could play a protective role in postmenopausal symptoms, osteoporosis, and cardiovascular health in humans (6) (7) (8) (9) . Thus, either in equol or non-equol producers, the effects of isoflavones containing genistein were dependent on whether genistein was the main component of isoflavone supplementation. However, the effects of isoflavones may also be due to daidzein or equol, because they also make up or are produced as a result of isoflavone supplementation. Importantly, to our knowledge, rare previous clinical trials have used daidzein as the only isoflavone source. Additionally, clinical studies have seldom used isoflavones with daidzein as the major component of the supplement (10) and previous studies have not reported the influence of equol status on the effects of isoflavones.
High circulating TG and LDL-cholesterol concentrations and low HDL-cholesterol concentrations are significant risk factors for cardiovascular disease (CVD). In the last decade, several systematic reviews and meta-analyses have assessed the effects of isoflavones on lipid profiles in humans (11) (12) (13) and led to various conclusions. The effects of isoflavones on lipid profiles is not yet clear due to the fact that different isoflavones were used in previous studies with differing durations of administration. In addition, single-nucleotide polymorphisms in ESR-a and b were associated with the effects of isoflavones on CVD. Hall et al. (14, 15) found that soy isoflavone-enriched foods significantly increased the HDL-cholesterol concentration in healthy postmenopausal women with ESR-b(cx) Tsp509I AA genotype and lowered plasma vascular cell adhesion molecule 1 in women with ESR-b AluI AA genotype.
In addition, uric acid was an independent risk factor of CVD (16) . The decrements of uric acid may contribute to the prevention or treatment of CVD (17) . In the Chinese population, serum uric acid concentrations were lower in the equol producers than in the non-equol producers (18) . Thus, isoflavone supplementation may also contribute to lowering uric acid concentrations.
To evaluate the effects of daidzein and equol status, we wanted to use daidzein as the only isoflavone source. We therefore performed a clinical trial using daidzein alone to assess the effects of daidzein supplement on cardiovascular risk factors and the interactions with equol status and ESR genotype. Other CVD risk factors (such as glycated hemoglobin and uric acid) were also assessed.
Materials and Methods
Population. Two hundred and ten patients with hypercholesterolemia were recruited into this clinical trial between May 2010 and June 2011 in Chongqing, China. The participants were screened in the regular physical examination databases of Chongqing populations and connected by telephone. Before recruiting, all volunteers underwent a complete physical examination and medical history investigation. The participants with a fasting total cholesterol concentration >5.18 mmol/L (200 mg/dL) were considered to be hypercholesterolemic. Eligible individuals also fell into these criteria: aged 40-65 y and a BMI (in kg/m 2 ) between 18 and 30. Exclusion criteria included familial hypercholesterolemia; a history of coronary heart disease, cancers, or severe liver or kidney dysfunction; use of cholesterol or lipid-lowering medications or insulin or dietary supplements such as fish oil, fiber, and isoflavones that may affect the lipid profiles; use of antibiotics; and postmenopausal women who received estrogen replacement therapy in the last 6 mo. Participants were allowed to continue taking blood pressure-lowering or hypoglycemic medications and were prohibited from the consumption of soy or isoflavones during the trial.
Study design. This study was a randomized, double-blind, placebocontrolled trial. Two hundred and ten eligible patients (108 men and 102 women) were randomly assigned to the soy isolated protein group (5 g/d) with 0 mg daidzein (placebo), 40 mg (DAI40), or 80 mg (DAI80). The randomized sequence was created through a randomization protocol using the SPSS system and the randomization information was sealed until the end of the study. The total intervention duration was 6 mo. All participants were asked to consume a low-fat, low-cholesterol diet, avoid the intake of soy or soy products, and maintain their habitual lifestyle during the study. Each participant attended our facility at 0, 3, and 6 mo. This protocol was approved by the Ethics Committee of the Third Military Medical University and all participants provided written informed consent. All procedures were in accordance with institutional guidelines and were carried out in compliance with the Helsinki Declaration.
Interventions. The placebo group was given 5 g/d soy isolated protein.
The DAI40 and DAI80 groups were given 5 g/d soy isolated protein supplemented with 40 and 80 mg/d daidzein, respectively. The soy isolated protein included 0.014% isoflavones, meaning that 5 g of soy isolated protein contained 0.7 mg isoflavones. All intervention products were a yellow powder and tasted of soy. These powders were packaged in sealed packets and looked identical. The participants were instructed to consume 1 packet/d combined with water, milk, or porridge every morning or evening. The packets were dispensed at 0 and 3 mo and the remaining packets were collected at 3 and 6 mo.
All participants were asked to complete a 3-d record of their food intake at baseline and 6 mo, which was analyzed by using the nutrition system of Chinese traditional medicine combined with western medicine (2009) software (Dong Chen) to estimate dietary nutrient intake. A questionnaire was given to each participant at the beginning of the trail (for baseline comparisons) and contained questions regarding lifestyle, disease history, medication, and nutrient supplements.
Equol status identification. Before the start of the trial, participants were asked to consume 150 g tofu for 3 consecutive days and then a first (day 4) urine sample was collected for equol producer identification. Urinary metabolites of isoflavones (genistein, daidzein, glycitein, and equol) were extracted using a method involving b-glucuronidase and sulphatase deconjugation and then daidzein and equol concentrations were assayed by HPLC (Waters) (19) . The participants with urinary equol concentrations >0.242 mg/L (1000 nmol/L) and a log 10 -transformed urinary S-equol:daidzein ratio > 21.75 (20) were identified as equol producers. Other participants not falling within these criteria were identified as non-equol producers.
Risk factor measurements. Assessment of serum fasting lipid profiles and glucose was performed using routine methods (BioSino Biotechnology and Science) in an automatic biochemical analyzer (7170S, Hitachi) (21) . Serum uric acid concentrations were assayed by a direct enzyme method (BioSino Bio-technology and Science) using the above analyzer. Serum lipoprotein(a) concentrations were determined by turbidimetric immunoassay (Ausbio Bio-technology) using the above analyzer. Blood glycated hemoglobin concentrations were determined by a latex agglutination inhibition assay (RANDOX Laboratories) in an automated analyzer (AIA-2000, Tosoh). Serum insulin was measured by an electrochemiluminescence immunoassay (Roche) in an automated immunoassay analyzer (Roche). All the above variables were determined at baseline and 6 mo. The within-and between-assay CVs were <5% for all laboratory methods.
DNA extraction and genotyping. DNA was extracted from the stored blood samples with DNA extraction kits (Aidlab Biotechnologies). ESRa (XbaI and PvuII) and b (AluI and RsaI) polymorphisms were measured by using PCR amplification (Bio-Rad) followed by enzymatic digestion with restriction endonucleases (PvuII, XbaI, AluI, or RsaI). The details of the primer sequences and PCR conditions were referenced in the study of Hall et al. (14) . The genotypes for ESR-a PvuII and XbaI polymorphic sites were characterized as CC/CT/TT and AA/AG/GG, respectively. The genotypes for ESR-b AluI and RsaI polymorphic sites were characterized as GG/GA/AA and GG/GA/AA, respectively.
Statistical analysis. The present study was designed to provide a >80% statistical power to detect 0.35 6 0.50 mmol/L of reduction in LDLcholesterol after a 6-mo intervention of soy isolated protein with 40 or 80 mg daidzein compared with a 0.10 6 0.50 mmol/L reduction after soy isolated protein intervention. The significance level was set at 0.05 and 2-tailed tests were used. It was estimated that a sample size of 209 was sufficient to test the primary LDL-cholesterol hypothesis while allowing for a 20% dropout rate.
All
Transformed data are presented as median (IQR). Outliers were excluded from analysis. All P values reported were 2-sided and <0.05 was considered significant. Differences in sex, equol status, ESR polymorphisms, and other categorical data among the 3 treatment groups were assessed by the chisquare method. Differences in measurement data among the 3 treatment groups at baseline and the end of the trial were evaluated by 1-factor ANOVA. The differences in measurement data at the end of the trial and baseline in each group were assessed by paired t test. The effects of the interventions on cardiovascular risk factors and the daily nutrients intakes of participants were assessed by 1-factor ANCOVA, with the change at 6 mo from baseline considered the dependent variable and the baseline value considered the covariate. Multiple comparison tests were performed using the Tukey method.
Data were also classified by sex, menopausal status, equol status, and ESR polymorphisms in each group to assess the effects of these variables on the daidzein effects. Three participants in the DAI40 group and 2 participants in the DAI80 group were the ESR-b RsaI AA genotype and were excluded from special analyses due to very small sample size. Because of the small sample size in each subgroup after classification, a combination of the DAI40 and DAI80 groups was using for all subgroup statistical analyses.
Results
Baseline characteristics. The baseline characteristics of participants in the 3 groups were similar ( Table 1) . In this trial, 76 women were postmenopausal and 10 were premenopausal. About one-fifth of participants suffered high blood pressure or diabetes and took blood pressure-or glucose-lowering medications. About one-fourth of participants were currently smoking or drinking. The distribution of menopausal status, equol status, and ESR genotypes did not differ among groups.
Compliance. During the study, 33 participants (17 men and 16 women) of the 210 randomly assigned participants dropped out. Four participants (2 men and 2 women) dropped out because of an unrelated disease. One man dropped out because of fears that isoflavones could affect his male characteristics. One perimenopausal woman in the DAI80 group dropped out because her menses started again. Twenty-seven participants (14 men and 13 women) withdrew because of low compliance with the protocol and they thought the protocol was too demanding. A total of 177 participants (91 men and 86 women) were included in the final analysis (Fig. 1) . No adverse reactions occurred during this trial. The overall participant compliance of this trial was excellent. According to recalled packet records, the rates of packet consumption were 93.2%, 94.3%, and 93.8% in the placebo, DAI40, and DAI80 groups, respectively. The main reasons for nonconsumption of treatment packets included forgetting to take the packet, participants going on trips for vacation or business, and bad taste.
Dietary nutrient intake. There were no significant differences in the daily mean dietary nutrient intake among the 3 groups at baseline and after 6 mo of supplementation ( Table 2) . Because participants were asked to avoid intake of soy and soy products during the study, the intakes of soy protein and isoflavones significantly decreased during treatment from baseline in each group. In addition, the daily energy, fat, and fiber intake in the placebo group; the daily fiber intake in the DAI40 group; and the daily energy, carbohydrates, proteins, fat, and fiber intake in the DAI80 group significantly decreased after the trial. There were no differences among the groups in the changes in intake for any nutrients.
Cardiovascular risk factors. Daidzein supplementation for 6 mo significantly decreased serum TG and uric acid concentrations but not in a dose-dependent manner (Table 3) . Compared with the placebo group, TGs decreased in the DAI40 and DAI80 groups (P < 0.05). However, there was no significant difference between the DAI40 and DAI80 groups. In participants with hypertriglyceridemia (baseline serum TG concentration >1.71 mmol/L), TGs decreased by 0.62 6 0.71 mmol/L (n = 27) in the DAI40 group and 0.69 6 0.71 mmol/L (n = 21) in the DAI80 group after treatment compared with the placebo group (n = 22; P < 0.05).
The reductions of the serum uric acid concentrations were different among the 3 treatment groups (P < 0.05); after 6 mo of treatment, the reduction was greater in the DAI80 groups than that in the placebo group (P < 0.05). There was no significant difference between the DAI40 and the placebo or between the DAI40 and DAI80 groups in terms of the reduction of uric acid. There was no significant difference in serum total, HDL-, and LDL-cholesterol; apoAI and B; lipoprotein(a); glucose; insulin; and blood glycated hemoglobin among groups after the treatment. No difference in the effects of daidzein between men and women or women with different menopausal status was noted.
Equol status. There were more equol producers in women (69%) than in men (51%) (P < 0.05) at baseline. At baseline, the mean (6SEM) concentrations of urinary equol and daidzein were 0.60 6 0.08 and 1.29 6 0.14 mg/L in equol producers and 0.015 6 0.002 and 1.30 6 0.24 mg/L in nonequol producers, respectively. Equol status did not influence the effects of daidzein on the blood lipid, glucose, insulin, glycated hemoglobin, or uric acid concentrations in hypercholesterolemic participants.
ESR polymorphisms. The changes in serum TGs due to supplemental daidzein were not different between the GA and GG genotypes of ESR-b RsaI in either the DAI40 or DAI80 group, but when they were pooled, the effect was greater in those bearing the GA compared with the GG genotype (Supplemental Fig. 1 ). ESR-a XbaI and PvuII, and ESR-b AluI genotypes did not influence the effects of daidzein on cardiovascular risk factors.
Discussion
A meta-analysis including 23 randomized, controlled, clinical trials reported that soy protein with isoflavones intact was associated with a decrease in TGs (by 0.10 mmol/L; 95% CI: 0.16, 0.05 mmol/L) (12) . In the present study, a greater reduction of TGs was found in the DAI40 and DAI80 group participants, especially in hypertriglyceridemic participants. The extent of TG reduction by daidzein was higher in our study than in other studies. This may be due to the effects of daidzein supplementation and the utilization of participants with high baseline TGs (mean in all population: 1.79 mmol/L). We also found that the ESR-b RsaI polymorphism influenced the reduction of TGs by daidzein. The ESR polymorphism has also been associated with CVD. In postmenopausal women undergoing coronary angiography, ESR-b AluI polymorphism was associated with obesity indices and cholesterol concentrations (22) . Additionally, the ESR-a PvuII polymorphism was associated with body fat content regulation in healthy men (23) , which was associated with cardiovascular risk factors such as obesity. In the current study, daidzein supplementation had a greater effect of decreasing TGs in the ESR-b RsaI GA genotype than in the GG genotype subgroup. Our results illustrated that the ESR-b RsaI polymorphism is associated with the effects of isoflavones on cardiovascular risk factors. Our current study also demonstrated that uric acid significantly decreased (by 23 6 47 mmol/L in the DAI40 group and 29 6 44 mmol/L in the DAI80 group) after daidzein intervention. However, Liu et al. (24) found that isoflavone (100 mg/d, major genistein) consumption for 6 mo did not influence uric acid among postmenopausal Chinese women with prediabetes or early untreated diabetes. Chen et al. (25) reported that 4 wk of genistein intervention had no effect on uric acid in healthy young men. These differences in findings may due to the different supplements used and differences in the participants between our study and other studies. The mechanism of daidzein-lowering uric acid may be related to the inhibition of xanthine oxidase, which is responsible for uric acid production. Previous studies demonstrated that oral treatment with soy isoflavones led to a significant decrease in xanthine oxidase in rats (26) , which supports our findings. Future studies will assess the effects of soy protein supplementation and/or isoflavones on uric acid in adults with hyperuricemia.
We demonstrated a higher prevalence of equol producers in women than in men, which was similar to the findings of a previous study. Liu et al. (19) found that the prevalence of equol producers in Chinese women tended to be higher than in men (64.0% and 56.7%, respectively). Previous studies suggested that isoflavones may have better health effects in equol producers than in non-equol producers (3). We found equol status had no influence on the improvement of TGs and uric acid by daidzein supplementation. Our findings did not support that daidzein had better health effects in equol producers than in non-equol producers. However, there was one limitation of our study. We identified the equol and non-equol producers at baseline and conducted statistical analyses. Thus far, no clinical study that evaluated equol status and isoflavone effects assessed equol status after isoflavone supplementation. However, equol producers and non-equol producer status could change after isoflavone interventions in postmenopausal and premenopausal women (27) . Thus, the interaction of equol status and daidzein effects may change if equol status was identified at the end of the supplementation period.
In conclusion, daidzein supplementation for 6 mo effectively decreased TG and uric acid concentration while having no effect on glucose and other lipids in hypercholesterolemic individuals. ESR-b RsaI genotype, not equol status, was associated with daidzein effects on TGs. Our findings suggest that daidzein may play an important role in the prevention and treatment of CVD.
